(Q43724371)

26 November 2017

title

Timing of quality of life (QoL) assessments as a source of error in oncological trials (English)

1 reference

26 November 2017

1 reference

12

Blomqvist C

1 reference

26 November 2017

4

Pluzanska A

1 reference

26 November 2017

Hakamies-Blomqvist L

1

1 reference

26 November 2017

Luoma ML

2

1 reference

26 November 2017

Sjöström J

3

1 reference

26 November 2017

Sjödin M

5

1 reference

26 November 2017

Mouridsen H

6

1 reference

26 November 2017

Østenstad B

7

1 reference

26 November 2017

Mjaaland I

8

1 reference

26 November 2017

Ottosson S

9

1 reference

26 November 2017

Bergh J

10

1 reference

26 November 2017

Malmström PO

11

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

Journal of Advanced Nursing

26 November 2017

published in

1 reference

26 November 2017

volume

35

1 reference

26 November 2017

issue

5

1 reference

26 November 2017

page(s)

709-716

1 reference

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Missing quality of life data in cancer clinical trials: serious problems and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Quality of life assessment in clinical trials--guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience. MRC Cancer Trials Office.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Methodological issues in the assessment of health-related quality of life in palliative care trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study G

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Quality of life as an endpoint in EORTC clinical trials. European Organization for Research and Treatment for Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

A clinical model for quality of life assessment in cancer patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

What has been learned from measuring health-related quality of life in clinical oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Interpreting the significance of changes in health-related quality-of-life scores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Evaluation of quality of life in patients receiving treatment for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2648.2001.01903.X

10.1046/J.1365-2648.2001.01903.X

21 January 2018

Identifiers

DOI

1 reference

release_vae7jcgux5ew7aw76t6ieokq5a

26 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vae7jcgux5ew7aw76t6ieokq5a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference